Recruitment begins in early Alzheimer's Phase 2 Elayta trial | Alzheimer's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
Recruitment has begun at the first clinical site of START, a Phase 2 study evaluating Elayta in adults with early Alzheimer's disease.| Alzheimer's News Today
CT1812 is an oral medication being developed by Cognition Therapeutics, now in clinical testing, to possibly treat mild-to-moderate Alzheimer’s disease by preventing the build up of beta-amyloid in the brain.| Alzheimer's News Today
No description.| Alzheimer's News Today
Category archive page for Columns.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today
